As you may already know, ADA Standards of Care are now the living standards which basically means updates are made in real time rather than once year. CREDENCE trial results revealed that the SGLT-2 inhibitor, canagliflozin, was associated with both reduced renal failure and cardiovascular events in persons with type 2 diabetes and chronic kidney disease. These are game changing results. Updates to sections 10 and 11 of the ADA Standards of Care have been made as a result of CREDENCE trial findings. A few highlights of the updates include…
- At least annual assessment of urinary albumin and estimated glomerular filtration (eGFR) rate in all persons with type 2 diabetes.
- GLP-1 agonist medication may lower risk for albuminuria risk progression and/or CV risk in persons with CKD at elevated risk of CV events.
- SGLT-2 inhibitor should be considered when eGFR is at or above 30 in persons with type 2 diabetes and chronic kidney disease especially with albuminuria above 300 mg/g to lower CV and renal risk.
To learn more, please click on links below.
Please share your thoughts and subscribe to receive my blogs.
#CREDENCE #ADA #updated #standards
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.